Robeco Institutional Asset Management B.V. raised its holdings in Manhattan Associates, Inc. (NASDAQ:MANH – Free Report) by 26.1% in the third quarter, Holdings Channel reports. The firm owned 160,740 shares of the software maker’s stock after purchasing an additional 33,241 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Manhattan Associates were worth $45,229,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently bought and sold shares of MANH. Norden Group LLC bought a new position in Manhattan Associates in the 1st quarter valued at $225,000. First Trust Direct Indexing L.P. bought a new position in Manhattan Associates in the 1st quarter valued at $393,000. Janney Montgomery Scott LLC grew its stake in Manhattan Associates by 5.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 4,338 shares of the software maker’s stock valued at $1,086,000 after purchasing an additional 218 shares during the period. Central Pacific Bank Trust Division bought a new position in Manhattan Associates in the 1st quarter valued at $509,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Manhattan Associates in the 1st quarter valued at $2,407,000. Institutional investors own 98.45% of the company’s stock.
Manhattan Associates Stock Up 0.9 %
NASDAQ:MANH opened at $266.64 on Tuesday. The business’s 50-day moving average price is $275.85 and its two-hundred day moving average price is $248.36. Manhattan Associates, Inc. has a twelve month low of $199.23 and a twelve month high of $307.50. The stock has a market cap of $16.29 billion, a P/E ratio of 75.75 and a beta of 1.52.
Wall Street Analysts Forecast Growth
MANH has been the subject of several research reports. DA Davidson increased their price target on Manhattan Associates from $285.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Raymond James increased their price target on Manhattan Associates from $255.00 to $305.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 23rd. Citigroup increased their price target on Manhattan Associates from $257.00 to $287.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 25th. Truist Financial increased their price target on Manhattan Associates from $275.00 to $310.00 and gave the stock a “buy” rating in a research note on Friday, October 11th. Finally, StockNews.com cut Manhattan Associates from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Manhattan Associates presently has a consensus rating of “Moderate Buy” and an average target price of $286.38.
Read Our Latest Report on MANH
About Manhattan Associates
Manhattan Associates, Inc develops, sells, deploys, services, and maintains software solutions to manage supply chains, inventory, and omni-channel operations. It offers Warehouse Management Solution for managing goods and information across the distribution centers; Manhattan Active Warehouse Management, a cloud native and version less application for the associate; and Transportation Management Solution for helping shippers navigate their way through the demands and meet customer service expectations at the lowest possible freight costs; Manhattan SCALE, a portfolio of logistics execution solution; and Manhattan Active Omni, which offers order management, store inventory and fulfillment, POS, and customer engagement tools for enterprises and stores.
Recommended Stories
- Five stocks we like better than Manhattan Associates
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Intel: Is Now the Time to Be Brave?Â
- Canadian Penny Stocks: Can They Make You Rich?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Want to see what other hedge funds are holding MANH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Manhattan Associates, Inc. (NASDAQ:MANH – Free Report).
Receive News & Ratings for Manhattan Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Manhattan Associates and related companies with MarketBeat.com's FREE daily email newsletter.